United States - English - NLM (National Library of Medicine)

physicians total care, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol - unii:817w3c6175) - brimonidine tartrate 2 mg in 1 ml - combigan® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of combigan® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. asthma, copd combigan® is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease (see warnings and precautions , 5.1, 5.3). sinus bradycardia, av block, cardiac failure, cardiogenic shock combigan® is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure (see wa

United States - English - NLM (National Library of Medicine)

allergan, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - brimonidine tartrate 2 mg in 1 ml - combigan ®   (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop; the iop-lowering of combigan ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. combigan ® is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [ see warnings and precautions   ( 5.1 , 5.3 ) ] . combigan ®   is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure [see warnings and precautions ( 5.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - brimonidine tartrate - ophthalmic solution - brimonidine tartrate 0.15 %w/v - brimonidine - brimonidine - for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1.5 mg in 1 ml - alphagan ® p (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. alphagan ® p is contraindicated in neonates and infants (under the age of 2 years). alphagan ® p is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with alphagan ® p 0.1% or 0.15%, 1 drop in both eyes three times daily. there are no adequate and well-

United States - English - NLM (National Library of Medicine)

allergan, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1 mg in 1 ml - alphagan ® p (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. alphagan ® p is contraindicated in neonates and infants (under the age of 2 years).  alphagan ® p is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved auc exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with alphagan ® p 0.1% or 0.15%, 1 drop in both eyes three times daily. there are no adequate and

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml - eye drops, solution - excipient ingredients: sodium hydroxide; purified water; sodium chloride; polyvinyl alcohol; citric acid; benzalkonium chloride; hydrochloric acid; sodium citrate dihydrate - indications: alphagan eye drops are effective as monotherapy for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension in whom (beta symbol)-blockers are not tolerated or are contraindicated. indications as at 7 december 1999: alphagan eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. alphagan eye drops can be used in the treatment of glaucoma either as monotherapy or in combination with topical beta-blockers.

Israel - English - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops, suspension - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - English - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops suspension - brimonidine tartrate 2 mg / 1 ml; brinzolamide 10 mg / 1 ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

galderma (uk - brimonidine tartrate - gel - 3mg/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - brimonidine tartrate - eye drops, solution - 0.2 percent weight/volume - sympathomimetics in glaucoma therapy1); brimonidine